Background: Sexually transmitted infections (STIs) represent significant risk factors for HIV transmission and adverse fetal complications in pregnancy. We tested 240 pregnant women for their HIV serostatus and for the effects of HIV-STI coinfections on CD4+ cell counts and on HIV plasma viral load. The study was conducted at four antenatal clinics in Akure, Ondo State of Nigeria between November 2014 and December 2015.
Introduction
Studies have shown that sexually transmitted diseases (STDs) such as Neisseria gonorrhea, Trichomonas vaginalis, Chlamydia trachomatis, human herpes simplex-2 (HSV-2) and human papilloma virus-6 (HPV-6) are significant risk factors for HIV transmission in women [1] . HIV infection in pregnant women may lead to adverse fetal outcomes, while co-infection of HIV with any STI during pregnancy may accelerate the development of fetal and maternal complications [2] . A recent study from Nigeria reported that infection with Trichomonas vaginalis increased the risk of HIV infection, while another study showed an HIV infection rate of 33% among women with infections of T. vaginalis. Studies from Zimbabwe reported that women with a history of genital ulcers and pelvic inflammatory disease were six times more likely to contract HIV than normal individuals [3] . Another study showed that improved STD treatment in a randomized controlled trial in Tanzania reduced the rate of new HIV infections, underscoring the role of STIs in HIV susceptibility. Epidemiological studies from sub-Saharan Africa, Europe and North America have suggested that there is approximately a four-times greater risk of becoming infected with HIV in the presence of a genital ulcer such as those caused by syphilis and chancroid [4] . Prevalenc e rates of syphilis as high as 30% have been described in antenatal women while 4.2% of women in a population-based study in Tanzania reported a history of genital ulcers [5] . Such co-infections may significantly increase HIV plasma viral load [6] . It was estimated that a 10-fold increase of plasma HIV RNA resulted in an 81% increased rate of HIV transmission [7, 8] . About 350-400 million people worldwide are chronically infected with HBV, with over a million individuals dying annually from HBV related complications [2] . HIV and HBV are two viruses with similar modes of transmission through sexual contact, mother-to-child transmission (MTCT) in pregnancy, breast-feeding and intravenous drug use [2] . While HIV and HBV have common modes of transmission, HBV has been shown to be about 100 times more infectious [8] . Our study investigated the frequency of HIV-STI coinfections and their effects on CD4+ cell count, HIV plasma viral load and liver enzyme elevations in 50% of HIV seropositive subjects and 22.2% for seronegative controls. HIV-HBV coinfection occurred among 7 individuals while HIV-HBV-TV coinfection occurred in 4 individuals. The results also showed elevated titers of alanine aminotransferase (ALT), creatinine and total bilirubin liver enzymes in both HIV-HBV coinfection and HBV monoinfection. HIV viral loads were twice as high in HIV-HBV coinfection relative to HBV mono-infection.
Conclusion:
The prevalence of STIs was significantly high at 54.4% among HIV seropositive pregnant women as compared to 14.3% for HIV seronegative pregnant women. T. vaginalis was the highest isolate at 50% in HIV seropositive subjects and may therefore be a driving factor for HIV transmission and susceptibility as very few T. vaginalis infections were recorded in control subjects. among HIV seropositive women who attended antenatal clinics at Akure in Ondo State of Nigeria. It is expected that the findings from our study would enable clinicians to better manage HIV coinfections in both pregnant and non-pregnant women so as to reduce complications that pose a risk for fetal mortality and maternal morbidity.
Methods

Study centers
This prospective study was conducted from November 2014 to December 2015 at four antenatal health care centers at Akure in Ondo State, Nigeria. The study included 240 participants, with 114 HIV seropositive and 126 seronegative women in their third trimester of pregnancy. The mean ages for the seropositive and seronegative women were 31.81 and 29.05 years respectively. Approval for the study was obtained from the Ondo State Hospital Management and Ethics committee, while informed consent was received from all participants following questionnaire responses and examination of case files managed by the attending physicians.
Inclusion Criteria
Informed consent, pregnancy in the third trimester and participation in the highly active antiretroviral therapy (HAART) were criteria for inclusion in the study. There was no age restriction for participation, as all subjects were required to keep all physician appointments throughout the study.
HIV screening
Blood was collected by venupuncture from each participant. A measured small aliquot was applied onto the HIV-1/2 strip (Determine Test, Alere, UK) for preliminary determination of HIV serostatus. Confirmatory test for HIV infection was performed using an ELISA procedure (Abbott Laboratories, Chicago, IL, USA).
Immunological Assessment
CD4+ cell counts were carried out by standard cytometric procedure following manufacturer's instructions (CyFlow SL-3, Partec, Germany ® ), and with the establishment of a baseline cell count [10] . The counts were repeated at 3 and 6 months later.
Viral load measurement
Serum aliquots from the whole blood collection were also used for the HIV viral load assessment. Serum was separated from whole blood by centrifugation at room temperature within 6 hours of blood collection, aliquoted, and frozen at -70 o C until processing for viral load measurement. The viral load (plasma HIV RNA copies) which quantifies the viral burden of HIV in the blood was assayed only in HIV seropositive subjects. The COBAS ® AmpliPrep TaqMan HIV-1 Qual test (version 3.2 series 3.3) kit was employed for the assay [11] .
Sexually transmitted infections (STIs)
Some sexually transmitted infections (STIs) among the study participants were determined using sera from both HIV infected and HIV non-infected pregnant women. Only clear non-haemolysed specimens were used. Specimens were brought to room temperature after being thawed. An automated chemistry analyser (Vitros 350) was employed for determination of liver enzymes following manufacturer's instructions. A modified ELISA method was used for detection of hepatitis B virus (HBV), hepatitis C virus (HCV), human papilloma virus-6 (HPV-6) and herpes simplex virus type-2 (HSV-2). A positive HBV infection was indicated by the demonstration of hepatitis B virus surface antigen (HBsAg). In this procedure, two drops of plasma were transferred to the cassettes containing coated antigen (Abon Biopharm (Hangzhou) Co. Ltd, Hangzhou, China). Thereafter, a drop of buffer (reagents A and B) was added to the cassettes and the assay was timed for 10 -20 minutes and visually observed for a formation of two red colored bands as an indication of a positive test. The rapid plasma reagin test (VDRL) was used for the detection of infection with Treponema pallidum, the causative agent of syphilis. T. vaginalis was detected by preparing a wet smear on a clean grease-free slide with a drop of sterile normal saline and high vaginal fluid sample collected from the subjects. Each participant presenting with T. vaginalis was initially examined for clinical symptoms of yellow discharge, abnormal vaginal odour, vulval itching and signs of colpitis macularis (''strawberry cervix'') purulent vaginal discharge and vulvar erythema. While sensitivity of symptoms and signs is relatively low, nonetheless, clinical manifestations are routinely used to identify patients for whom wet mount examination would likely have low yield. Subsequently, the wet mount slide was examined under the microscope for highly motile tiny spear shaped flagellates with an axostyle. This slide examination was performed within 10 to 20 min of sample collection.
The presence of Chlamydia trachomatis in high vaginal swab sample was determined by an enzyme immunosorbent assay (EIA) using cervical mucus obtained from the vaginal posterior fornix of each subject. Each sample was introduced into a cassette containing coated antigen, rinsed by buffer (reagents A and B), processed according to the instructions of the manufacturer (ABON, Abon Biopharm (Hangzhou) Co., Ltd., Hangzhou, China) and visually observed also for a formation of two colored bands as an indication of a positive test.
Similarly, high vaginal swab was collected from the posterior fornix from each pregnant subject by the attending physician using sterile bivalve speculum (Changzhou Huankang Medical Devices Co. Ltd, Changzhou City, China) and sterile cotton-tipped applicator (Evepon Industrial Limited, Onitsha, Anambra, Nigeria) into freshly prepared sterile thioglycollate medium and incubated at 37 o C for 24 h for growth. Thereafter a loopful of the sample was streaked onto freshly prepared agar plates (proteose peptone agar supplemented with 5% serum) for isolation of N. gonorrhoeae. The organism was identified by sugar fermentation test that included glucose, maltose, sucrose and lactose. Only gram negative diplococci isolates with bean-shaped colonies that were also positive for glucose fermentation were confirmed as N. gonorrhoeae.
Statistical Analysis of Data
Statistical evaluation was done using student t-test and one-way analysis of variance (ANOVA) with p ≤ 0.05 as a measure of statistical significance. SPSS (Chicago, IL, SPSS Inc., 2007) version 17.0 for Windows ® was used to perform the analysis. 2 show the distribution of sexually transmitted infections (STIs) among HIV seropositive and seronegative pregnant women in the study po- Table 4 also shows that the mean prenatal and postnatal plasma HIV viral loads for the HIV-HBV coinfected women were respectively 8,787 and 4,705 RNA copies/mL, which were significantly much higher than the 7,830 and 3,363 RNA copies/mL for the HIV mono-infected women. These numbers again show a correlation between increased HIV viral load and lower CD4+ cell counts. The results also show that the prenatal mean titers of ALT (59 IU/L), creatinine (43mg/dL) and bilirubin (11mg/dL) and also the postnatal titers of HIV-HBV coinfected women were 10 -20 times higher than those of normal seronegative women. These increases in the liver enzyme titers reflect the deleterious inflammatory effect of HBV co-infection in HIV seropositive women.
Results
Tables 1 and
Discussion
The study investigated the prevalence of coinfection of HIV with selected sexually transmitted infections as well as their effects on the CD4 + cell counts, plasma HIV viral loads, and liver enzymes among 114 HIV seropositive pregnant women at antenatal clinics in Akure, Ondo State between November 2014 and December 2015. HIV seronegative pregnant women in the third trimester of pregnancy served as controls. The study revealed the remarkable effect of STI co-infections in the prognosis of HIV infection among HIV seropositive pregnant women. Sixty two (54.4%) of the HIV seropositive pregnant women had a co-infection of one or more STI, compared to 18 (14.3%) of HIV seronegative pregnant women. Interestingly, 31 (50%) of the 62 HIV seropositive pregnant women with STI coinfections had a co-infection of T. vaginalis, while five to seven co-infected women had a co-infection with HBV, HSV-2, HPV-6, T. pallidum and N. gonorrhoeae. These observations would suggest and that STIs, particularly T. vaginalis, may constitute a significant risk factor for HIV susceptibility in women. The preponderance of T. vaginalis infection among HIV seropositives is particularly interesting in many instances [12] , as other studies have noted that T. vaginalis infection may expand the portal of entry for HIV in exposed individuals, thus facilitating HIV transmission and increasing HIV shedding [13, 14] . Investigators have reported that wet mount procedure that is often used for T. vaginalis screening seems to have a low sensitivity of about 70%. Nonetheless, clinical symptoms have been used to supplement the diagnosis of infected patients [15] . Findings from this and other studies suggest that T. vaginalis and HIV may predispose one to another and vice versa [14] . Given the current availability of antiretroviral drugs in developing countries and the contribution of T. vaginalis infection on HIV transmission, it is evident that appropriate and prompt treatment of T. vaginalis infection would be essential to reducing the incidence of HIV infection [14] . Some studies have reported that HBV and HIV coinfection may not play a significant role in HIV disease progression [16] but that antiretroviral therapy may increase the risk of hepatotoxicity when starting HIV therapy [17] and also elevating the risk of hepatic flares when active treatment for both HIV and HBV is disrupted [18] . The effects of HIV coinfection with HBV on CD4 cell counts, HIV viral load and liver enzymes were also evaluated in our study. While the ALT value in normal individuals is ≤ 19 IU/L for women, the value was however elevated in HIV-HBV coinfection. ALT is a marker of liver inflammation or other hepatocyte damage. However, it has been shown that normal ALT levels can also be associated with liver disease progression, particularly in HBeAg negative and HIV coinfected patients. Our results show that the mean CD4+ T cell counts and plasma viral loads among the 7 individuals both at antenatal and post natal periods were significantly different. We also noted abnormal high titers of ALT of 59 -75 IU/L, creatinine at 43-50mg/dL and total bilirubin of 11-35mg/ dL at both antenatal and postnatal periods. These high values in Table 4 are indicative of progressive liver damage [19, 20, 21] . Analysis of the profile of the four others with three HIV-HBV-TV coinfections showed a mean CD4+ T cell count of 314.75 cells/ mm 3 compared to 405.3 cells/mm 3 for three individuals with only HIV-HBV coinfection. The mean viral load of the women with three coinfections was 4,375.5 RNA copies/mL, compared to 1,255 RNA copies/mL for the HIV-HBV coinfected individuals, thus representing a threefold decrease. The results of this study suggest that HIV coinfection with T. vaginalis may amplify and facilitate HIV infection. Our study is important in that it comprehensively evaluated the effect of STIs in HIV progression among HIV seropositive women in the third trimester of their pregnancy. The pathological complications to mother and fetus that may result from HIV-STI coinfections may result in multiple organ damage and lead to severe development fetal complications as well maternal morbidity and mortality.
Conclusion
In conclusion, our study showed the high prevalence of STIs among HIV seropositive pregnant women, with about a four-fold increase (54.4%) over the 14.3% prevalence among the HIV seronegative controls. The study also revealed that T. vaginalis was the predominant STI among the HIV-STI coinfected seropositive group (50%) as compared to the 22.2% among the HIV seronegative mothers. The study compared the mean CD4+ cell count, plasma viral load and liver enzymes among selected 7 individuals with HIV-HBV coinfection and showed that the mean CD4+T cell and plasma viral load at antenatal period was 327cells/mm 3 and 8,787 RNA copies/mL respectively while mean CD4+T cell count and plasma viral load at postnatal period were 337.25 cells/mm 3 and 4,705 RNA copies/mL Similarly, results from the liver enzymes (ALT, creatinine, total bilirubin) also revealed no significant difference in values in both the antenatal and postnatal period among the subjects [17, 18] .
Limitation of the Study:
The sensitivity of the techniques employed may have posed some limitation in the study. The detection of T. vaginalis by wet mount, syphilis by non treponemal rapid plasma reagin and C. trachomatis may have lowered sensitivity values. We are nonetheless, aware of sensitive techniques such as nucleic acid test (NAT) for gonorrhoea as well as immunofluorescence for DNA amplification for C. trachomatis both of which are often not available in resource constraint centers.
